Corporate Counsel Litigation Forum: Strategies & Trends in Effective Value-Based Billing
Webinar | 06.23.15, 10:00 AM EDT - 11:00 AM EDT
Please click here for a copy of the presentation.
For in-house counsel only, Crowell & Moring panelists and pricing experts will discuss "business of the law" trends in value-based billing (VBB) arrangements and their priorities and goals for dealing with those trends in 2015.
The panel will take questions and engage participants in a discussion of at least the following topics:
- What types of value-based billing arrangements are we seeing in hiring outside counsel? Which arrangements are working best?
- How are law firms meeting client needs in these areas and delivering value? What else can be done?
- What are the challenges and how are they being overcome?
Panelists:
- Robert A. Lipstein, Crowell & Moring Senior Counsel
- Dr. Silvia Hodges Silverstein, Executive Director and Founder of the Buying Legal Council
- Justin Ergler, Director of Alternative Fee Intelligence and Analytics at GlaxoSmithKline
- Matthew Laws, Crowell & Moring Sr. Director of Practice Management
Moderator:
Jerry Murphy, Crowell & Moring Partner
We hope you are able to join us for this webinar.
Click for more on Crowell & Moring's Corporate Counsel Litigation Forum webinar series.
Click to download our Handbook for Value-Based Billing Engagements [PDF].
For more information, please visit these areas: Intellectual Property Litigation, Product Risk Management, Government Contracts , Environment and Natural Resources, International Trade, International Dispute Resolution, Tax, Labor and Employment, Corporate and Transactional, Litigation and Trial, Intellectual Property, Corporate Counseling, Governance and Compliance
Insights
Webinar | 12.10.26
The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations
The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.
Webinar | 11.17.26
Webinar | 11.05.26
